Nodepress Capsule
Fluoxetine
20mg
Kemiko Pharmaceuticals Ltd.
| Pack size | 50's pack |
|---|---|
| Unite Price | 2.60 BDT |
Indications
Nodepress Capsule is used for:
Panic disorder, Obsessive compulsive disorder, Trichotillomania, Premenstrual dysphoric disorder, Major depression, Post-traumatic stress disorder, Bulimia nervosa, Body dysmorphic disorder, Binge eating disorder
Adult Dose
Oral
Depression
Adult: Initially, 20 mg once daily. May gradually increase up to max 80 mg daily in 2 divided doses, if no clinical response after several wk.
Bulimia nervosa
Adult: 60 mg daily as a single or in divided doses.
Hepatic impairment: Reduce dose and/or dosing frequency.
Obsessive compulsive disorder
Adult: Initially, 20 mg once daily, increased up to 60 mg daily if no clinical response after several wk. Max: 80 mg daily in 2 divided doses.
Premenstrual dysphoric disorder
Adult: 20 mg daily continuously. Alternatively, 20 mg daily to be started 14 days before menstruation and continued until 1st day of menses; repeat w/ each cycle.
Panic disorder
Adult: Initially, 10 mg once daily, increase to 20 mg daily after a wk. May further increase to 60 mg daily, if no clinical response after several wk.
Elderly: Max: 60 mg daily.
Hepatic impairment: Reduce dose and/or dosing frequency.
Child Dose
Oral
Depression
Child: >8 yr Initially, 10 mg daily, may increase to 20 mg daily after 1-2 wk.
Low wt childn: Initially, 10 mg daily, may increase to 20 mg daily after several wk, only if clinical response is insufficient.
Obsessive compulsive disorder
Child: >7 yr Initially, 10 mg daily, may increase to 20 mg daily after 2 wk; increase further up to 60 mg daily after several wk as necessary.
Low-wt childn: Initially, 10 mg daily, may increase to 20-30 mg daily after several wk, if required.
Renal Dose
Renal impairment: Use caution; drug accumulation may occur with severe renal impairment
Administration
May be taken with or without food.
Contra Indications
Severe renal or hepatic failure; hypersensitivity; lactation; concomitant MAOIs or within 2 wk of MAOI withdrawal.
Precautions
Unstable epilepsy, liver and renal impairment, cardiac disease, diabetes, electroconvulsive therapy, bleeding disorders, closed-angle glaucoma; pregnancy. May impair performace of skilled tasks; withdraw gradually. Close monitoring of clinical worsening and behavioural changes during the 1st few mth of treatment or when there are dose changes.
Lactation
Excreted in milk; avoid (AAP states effect on nursing infants is unknown but may be of concern)
Pregnancy-Lactation
Pregnancy category: C
Treatment of pregnant women during the first trimester: There are no adequate and well-controlled clinical studies on the use of fluoxetine in pregnant women, but 1 prospective cohort study conducted by the European Network of Teratology Information Services reported an increased risk of cardiovascular malformations in infants born to women (N = 253) exposed to fluoxetine during the first trimester of pregnancy, compared with infants of women (N = 1359) who were not exposed to fluoxetine
Use late in the third trimester associated with complications in newborns and may require prolonged hospitalization, respiratory support, and tube feeding
When treating a pregnant woman with fluoxetine, physician should carefully consider trimester both for the potential risks of taking an SSRI, along with the established benefits of treating depression with an antidepressant; the decision can only be made on a case by case basis
Lactation
Excreted in milk; avoid (AAP states effect on nursing infants is unknown but may be of concern)
Interactions
May cause transient shift in plasma conc of tightly protein bound drugs e.g. warfarin and digoxin, resulting in adverse effects. T1/2 of diazepam is prolonged. Avoid concurrent use with clopidogrel.
Potentially Fatal: Serious reactions when combined with MAOIs; at least 14 days should elapse after MAOIs withdrawal before starting fluoxetine treatment or at least 5 wk should elapse after fluoxetine treatment before starting MAOIs therapy. Two-fold increase in plasma levels of other antidepressants when combined with fluoxetine. Monitor lithium levels when combined.
Side Effects
Side effects of Fluoxetine :
>10%
Headache (20-25%), Nausea (12-29%), Insomnia (10-33%), Anorexia (4-17%), Anxiety (6-15%), Asthenia (10-15%), Diarrhea (8-18%), Nervousness (8-14%), Somnolence (5-17%), Tremor (3-13%), Weakness (7-21%)
1-10%
Dizziness (9%), Dry mouth (6-10%), Dyspepsia (6-10%), Sweating (5-10%), Decreased libido (2-5%), Abnormal taste (>1%), Agitation (>1%), Chest pain (>1%), Chills (>1%), Confusion (>1%), Ear pain (>1%), Hypertension (>1%), Increased appetite (>1%), Palpitation (>1%), Sleep disorder (>1%), Tinnitus (>1%), Urinary frequency (>1%), Vomiting (>1%), Weight gain (>1%)
Frequency Not Defined
Dysglycemia in patients with DM
Risk of seizure with concomitant electroconvulsive therapy (rare)
Potentially Fatal: Rarely, systemic events possibly related to vasculitis have been reported in patients with rash but may be serious involving lungs, kidney and liver.
Mode of Action
Fluoxetine is a potent and highly selective inhibitor of serotonin (5-HT) re-uptake. No affinity for adrenoceptors or histamine, GABA-B, or muscarinic receptors.
Note
Nodepress 20mg Capsule generic name is Fluoxetine. Nodepress 20mg Capsule is manufactured by Kemiko Pharmaceuticals Ltd.Nodepress is availble in all over Bangladesh.
Mes BD drug index information on Nodepress Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.